AZENTA INC(NASDAQ:AZTA) stock Fundamental Analysis

Fundamental Rating

Overall AZTA gets a fundamental rating of 5 out of 10. We evaluated AZTA against 55 industry peers in the Life Sciences Tools & Services industry. AZTA has a great financial health rating, but its profitability evaluates not so good. AZTA is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

AZTA had positive earnings in the past year.

In the past year AZTA had a positive cash flow from operations.

The reported net income has been mixed in the past 5 years: AZTA reported negative net income in multiple years.

AZTA had a positive operating cash flow in 4 of the past 5 years.

1.2 Ratios

AZTA has a Return On Assets (-7.93%) which is comparable to the rest of the industry.

AZTA has a better Return On Equity (-9.41%) than 61.82% of its industry peers.

		Industry Rank	Sector Rank
ROA	-7.93%
ROE	-9.41%
ROIC	N/A

ROA(3y)16.36%

ROA(5y)11.87%

ROE(3y)17.86%

ROE(5y)13.45%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

AZTA's Gross Margin of 41.65% is in line compared to the rest of the industry. AZTA outperforms 43.64% of its industry peers.

AZTA's Gross Margin has been stable in the last couple of years.

AZTA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	41.65%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-5.44%

GM growth 5Y-0.19%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AZTA does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for AZTA has been reduced compared to 1 year ago.

Compared to 5 years ago, AZTA has less shares outstanding

AZTA has a worse debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 3.80 indicates that AZTA is not in any danger for bankruptcy at the moment.

With a decent Altman-Z score value of 3.80, AZTA is doing good in the industry, outperforming 74.55% of the companies in the same industry.

AZTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	3.8

ROIC/WACCN/A

WACC10.59%

2.3 Liquidity

A Current Ratio of 4.18 indicates that AZTA has no problem at all paying its short term obligations.

Looking at the Current ratio, with a value of 4.18, AZTA is in the better half of the industry, outperforming 65.45% of the companies in the same industry.

A Quick Ratio of 3.78 indicates that AZTA has no problem at all paying its short term obligations.

With a decent Quick ratio value of 3.78, AZTA is doing good in the industry, outperforming 67.27% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4.18
Quick Ratio	3.78

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 113.64% over the past year.

The earnings per share for AZTA have been decreasing by -12.07% on average. This is quite bad

Looking at the last year, AZTA shows a small growth in Revenue. The Revenue has grown by 1.33% in the last year.

The Revenue has been decreasing by -3.41% on average over the past years.

EPS 1Y (TTM)113.64%

EPS 3Y-45.83%

EPS 5Y-12.07%

EPS Q2Q%300%

Revenue 1Y (TTM)1.33%

Revenue growth 3Y8.51%

Revenue growth 5Y-3.41%

Sales Q2Q%-4.41%

3.2 Future

Based on estimates for the next years, AZTA will show a very strong growth in Earnings Per Share. The EPS will grow by 29.43% on average per year.

AZTA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.23% yearly.

EPS Next Y25.1%

EPS Next 2Y42.83%

EPS Next 3Y35.14%

EPS Next 5Y29.43%

Revenue Next Year-9.42%

Revenue Next 2Y-2.27%

Revenue Next 3Y0.03%

Revenue Next 5Y2.23%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 54.89, which means the current valuation is very expensive for AZTA.

AZTA's Price/Earnings is on the same level as the industry average.

Compared to an average S&P500 Price/Earnings ratio of 28.64, AZTA is valued quite expensively.

With a Price/Forward Earnings ratio of 30.85, AZTA can be considered very expensive at the moment.

Based on the Price/Forward Earnings ratio, AZTA is valued a bit cheaper than 63.64% of the companies in the same industry.

AZTA's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 21.44.

		Industry Rank	Sector Rank
PE	54.89
Fwd PE	30.85

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AZTA is valued a bit cheaper than the industry average as 65.45% of the companies are valued more expensively.

Based on the Price/Free Cash Flow ratio, AZTA is valued a bit cheaper than the industry average as 61.82% of the companies are valued more expensively.

		Industry Rank	Sector Rank
P/FCF	57.7
EV/EBITDA	21.93

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates AZTA does not grow enough to justify the current Price/Earnings ratio.

AZTA's earnings are expected to grow with 35.14% in the coming years. This may justify a more expensive valuation.

PEG (NY)2.19

PEG (5Y)N/A

EPS Next 2Y42.83%

EPS Next 3Y35.14%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for AZTA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

AZENTA INC

NASDAQ:AZTA (4/23/2025, 8:00:01 PM)

Premarket: 25.1 -0.7 (-2.71%)

25.8

+0.75 (+2.99%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryLife Sciences Tools & Services

Earnings (Last)02-05 2025-02-05/bmo

Earnings (Next)05-12 2025-05-12/amc

Inst Owners115.49%

Inst Owner ChangeN/A

Ins Owners0.69%

Ins Owner Change13.48%

Market Cap1.18B

Analysts71.43

Price Target56.1 (117.44%)

Short Float %9.44%

Short Ratio7.51

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend0

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)54.54%

Min EPS beat(2)37.26%

Max EPS beat(2)71.81%

EPS beat(4)4

Avg EPS beat(4)98.59%

Min EPS beat(4)37.26%

Max EPS beat(4)162.56%

EPS beat(8)7

Avg EPS beat(8)212.82%

EPS beat(12)11

Avg EPS beat(12)159.27%

EPS beat(16)14

Avg EPS beat(16)124.06%

Revenue beat(2)0

Avg Revenue beat(2)-1.39%

Min Revenue beat(2)-1.7%

Max Revenue beat(2)-1.07%

Revenue beat(4)1

Avg Revenue beat(4)-0.82%

Min Revenue beat(4)-2.43%

Max Revenue beat(4)1.9%

Revenue beat(8)4

Avg Revenue beat(8)-0.51%

Revenue beat(12)6

Avg Revenue beat(12)-0.88%

Revenue beat(16)7

Avg Revenue beat(16)-11.36%

PT rev (1m)-1.28%

PT rev (3m)-0.3%

EPS NQ rev (1m)1.89%

EPS NQ rev (3m)42.09%

EPS NY rev (1m)0.57%

EPS NY rev (3m)22.22%

Revenue NQ rev (1m)-0.17%

Revenue NQ rev (3m)-3.37%

Revenue NY rev (1m)-0.1%

Revenue NY rev (3m)-0.43%

Valuation

		Industry Rank	Sector Rank
PE	54.89
Fwd PE	30.85
P/S	1.82
P/FCF	57.7
P/OCF	21.64
P/B	0.69
P/tB	1.27
EV/EBITDA	21.93

EPS(TTM)0.47

EY1.82%

EPS(NY)0.84

Fwd EY3.24%

FCF(TTM)0.45

FCFY1.73%

OCF(TTM)1.19

OCFY4.62%

SpS14.21

BVpS37.61

TBVpS20.36

PEG (NY)2.19

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-7.93%
ROE	-9.41%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	41.65%
FCFM	3.15%

ROA(3y)16.36%

ROA(5y)11.87%

ROE(3y)17.86%

ROE(5y)13.45%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-5.44%

GM growth 5Y-0.19%

F-Score6

Asset Turnover0.32

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	0
Cap/Depr	39.15%
Cap/Sales	5.24%
Interest Coverage	N/A
Cash Conversion	189.73%
Profit Quality	N/A
Current Ratio	4.18
Quick Ratio	3.78
Altman-Z	3.8

F-Score6

WACC10.59%

ROIC/WACCN/A

Cap/Depr(3y)77.14%

Cap/Depr(5y)74.64%

Cap/Sales(3y)8.52%

Cap/Sales(5y)9.22%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)113.64%

EPS 3Y-45.83%

EPS 5Y-12.07%

EPS Q2Q%300%

EPS Next Y25.1%

EPS Next 2Y42.83%

EPS Next 3Y35.14%

EPS Next 5Y29.43%

Revenue 1Y (TTM)1.33%

Revenue growth 3Y8.51%

Revenue growth 5Y-3.41%

Sales Q2Q%-4.41%

Revenue Next Year-9.42%

Revenue Next 2Y-2.27%

Revenue Next 3Y0.03%

Revenue Next 5Y2.23%

EBIT growth 1Y14.17%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year1016.06%

EBIT Next 3Y152.04%

EBIT Next 5YN/A

FCF growth 1Y103.52%

FCF growth 3Y-48.98%

FCF growth 5Y-28.07%

OCF growth 1Y110.71%

OCF growth 3Y-30.52%

OCF growth 5Y-11.17%

AZENTA INC (AZTA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens